Quote | Sema4 Holdings Corp. (NASDAQ:SMFR)
Last: | $0.3106 |
---|---|
Change Percent: | -4.45% |
Open: | $0.2559 |
Close: | $0.3106 |
High: | $0.3306 |
Low: | $0.2534 |
Volume: | 4,704,920 |
Last Trade Date Time: | 01/09/2023 03:40:58 pm |
News | Sema4 Holdings Corp. (NASDAQ:SMFR)
Sema4 Holdings ( NASDAQ: SMFR ) rose ~7% after the company said it has its changed name and ticker symbol and issued higher Y/Y 2022 revenue guidance. SMFR changed its name to GeneDx Holdings, with the ticker symbol of WGS. The class A shares will begin trading on Nasdaq under the...
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
Message Board Posts | Sema4 Holdings Corp. (NASDAQ:SMFR)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $WGS 41% v4,3M c.5050 f798,247M H.52 ML.272 | znewcar1 | investorshangout | 03/20/2023 10:35:44 PM |
$SMFR...MGS..READY TO RUMBLE!! | TrendTrade2016 | investorshub | 01/11/2023 9:10:43 AM |
znewcar1: $SMFR 26% v4,7M c.3106 f386,795M H.3306 ML.22 YL.235 gapNgo | znewcar1 | investorshangout | 01/09/2023 11:02:35 PM |
$SMFR here we go...monster in the making | TrendTrade2016 | investorshub | 01/09/2023 6:10:26 PM |
$SMFR breaking out | TrendTrade2016 | investorshub | 01/09/2023 3:34:29 PM |
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Company Name:
SMFR Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...